title: Hemophilia management in transfusion medicine.
abstract: Hemophilia is an X-linked bleeding disorder caused by a deficiency of factor VIII or IX activity. We will review the use of blood products, including plasma derived and recombinant coagulation factor concentrates (CFCs), and other hemostatic agents central to the management of bleeding, surgical procedures, prophylaxis and inhibitors. However, management of hemophilia is more than just giving CFCs. Attention to the physical and psychosocial health of persons with hemophilia to improve their quality of life must be the goal. These goals can best be met by comprehensive care hemophilia (bleeding disorders) clinics designed to provide clinical service and education to persons with hemophilia and their families, and to conduct research to improve hemophilia care.
authors.affiliation: The Department of Medicine and The Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada. mcpoon@ucalgary.ca
authors.forename: Man-Chiu
authors.initials: MC
authors.lastname: Poon
authors.forename: Robert
authors.initials: R
authors.lastname: Card
mesh_terms: D016913:Blood Component Transfusion; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005340:Fibrinogen / Q000627:therapeutic use*; D006467:Hemophilia A / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D010949:Plasma; D011788:Quality of Life
chemical_list: C026912:cryoprecipitate coagulum; C078147:F8 protein, human; D005169:Factor VIII; D005164:Factor IX; D005340:Fibrinogen